Market Overview

NetworkNewsBreaks – Axcella Health Inc. (NASDAQ: AXLA) Secures $60.1M in Underwritten Public Offering

Share:

Axcella Health (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators ("EMMs") to pioneer a new approach for treating complex diseases and improving health, has closed an underwritten public offering of 12,650,000 shares of its common stock, including 1,650,000 additional shares per the full exercise of the over-allotment option granted to the […]

Axcella Health (NASDAQ:AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators ("EMMs") to pioneer a new approach for treating complex diseases and improving health, has closed an underwritten public offering of 12,650,000 shares of its common stock, including 1,650,000 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Axcella secured approximately $60.1 million in gross proceeds, with each of the shares sold at the public offering price of $4.75. Axcella intends to use the proceeds, together with its existing cash and cash equivalents, to advance its current programs and product candidates, development platform and discovery efforts, as well as to support organizational growth and for working capital and other general corporate purposes. ROTH Capital Partners acted as co-manager for the offering.

To view the full press release, visit http://nnw.fm/iDX6I

About Axcella Health

Axcella is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators ("EMMs") to pioneer a new approach for treating complex diseases and improving health. The company's product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella's pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis ("NASH") and the reduction in risk of overt hepatic encephalopathy ("OHE") recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, visit the company's website at www.AxcellaHealth.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com